Cost vs Efficacy · 5 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
mFOLFOX6 and Cetuximab Variant #03 | RAS | R 57 509 | 14d | ~8.2 mo | ~30.9 mo | ~12 | ~R 328 700 PFS proxy · indirect | 4 |
mFOLFOX6-B Variant #01 | — | R 13 521 | 14d | ~9.7 mo | ~29.0 mo | ~2 | ~R 27 041 PFS proxy · indirect | 12 |
FLOX Variant #01 | — | R 11 881 | 56d | — | — | ~3 | ~R 35 644 indirect | — |
Tegafur, Uracil, Folinic acid Variant #01 Partial | — | R 11 824 | 35d | — | — | ~5 | ~R 59 119 indirect | — |
FULV Variant #29 | — | R 3 601 | 14d | — | — | 2 | R 7 201 PFS proxy | 1 |
CapeOx Variant #01 | — | R 2 620 | 21d | — | — | 6 | R 15 719 PFS proxy | 1 |
mFOLFOX6 Variant #02 | — | R 2 617 | 14d | ~8.4 mo | ~12.7 mo | ~12 | ~R 31 399 PFS proxy · indirect | 15 |
mFOLFOX6 Variant #02 | RAS | R 2 617 | 14d | ~8.4 mo | ~12.7 mo | ~12 | ~R 31 399 PFS proxy · indirect | 15 |
FOLFOX4 Variant #01 | — | R 2 374 | 14d | — | — | 3 | R 7 122 PFS proxy | 1 |
mFOLFOX6 (L-Leucovorin) Variant #01 Partial | — | R 2 054 | 14d | — | ~11.8 mo | ~2 | ~R 4 107 PFS proxy · indirect | 3 |
FULV and Levamisole Variant #01 Partial | — | R 2 014 | 35d | — | — | 4 | R 6 043 PFS proxy | 1 |
SOX Variant #01 Partial | — | R 1 265 | 21d | ~5.6 mo | — | ~2 | ~R 2 530 PFS proxy · indirect | 3 |
Capecitabine monotherapy Variant #01 | — | R 1 039 | 21d | — | — | 8 | R 8 309 PFS proxy | 1 |
MOF Variant #01 Partial | — | R 933 | 70d | — | — | ~8 | ~R 7 465 indirect | — |
Fluorouracil monotherapy Variant #01 | — | R 647 | 28d | — | ~10.0 mo | ~2 | ~R 1 294 PFS proxy · indirect | 3 |
Fluorouracil and Levamisole Variant #01 Partial | — | R 566 | 28d | — | — | 11 | R 2 184 PFS proxy | 1 |
Edrecolomab monotherapy Variant #01 Partial | — | — | 28d | — | — | ~4 | — | — |
BCG vaccine monotherapy Variant #01 Partial | — | — | 30d | — | ~38.6 mo | ~1 | — | 1 |
S-1 monotherapy Variant #01 Partial | — | — | 21d | ~1.7 mo | ~10.5 mo | ~2 | — | 13 |
19 of 19 regimens shown